生物试剂
>
生化试剂
>
信号通路
> 维多珠单抗
加入收藏 取消收藏

维多珠单抗  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：10mg in glass bottle
产品描述：基本信息 产品编号：V10119 产品名称：Vedolizumab CAS: 943609-66-3   储存条件 粉末 -20℃ 四年 分子式：   溶于液体 -80℃ 六个月 分子量       化学名：      Solubility (25°C)   体外 DMSO   Ethanol   Water   体内（现配现用）     ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   生物活性 产品描述 一种靶向α4β7整联蛋白 (integrin) 的人源化单克隆抗体，用于溃疡性结肠炎和克罗恩病的相关研究。 靶点/IC50 Integrin   体外研究 Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%),neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC50=0.3-0.4nM).Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC50=0.02-0.06g/mL) and fibronectin (IC50=0.02g/mL), but not vascular cell adhesion molecule 1. 体内研究 Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab.The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5μg/mL in those receiving 0.5mg/kg of vedolizumab and 52.0μg/mL in those receiving 2mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study,the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups.   推荐实验方法(仅供参考) 激酶实验： Vedolizumab inhibition of high-affinity binding of MAdCAM-1 to human peripheral blood memory CD4+ T lymphocytes is tested.Peripheral blood (90μL) is incubated with a saturating concentration (3μg/mL) of MAdCAM-1-murine-Fc fusion protein and 4mM MnCl2 in a final volume of 100μL for 1 h at room temperature,in the presence or absence of vedolizumab.After washing with assay buffer, the cells are stained with fluorescentlabeled anti-mouse IgG for 15min at room temperature. After washing again, cells are incubated with mouse serum for 10min at room temperature,followed by staining with anti-CD4 and anti-CD45RO antibodies for 15min at room temperature. After washing, red blood cells are lysed with BD FACS lysing solution and analyzed by flow cytometry in a FACSCalibur with CellQuest Pro software.
保存条件：-20℃

猜你喜欢